To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology-Reference-Cited by-同舟云学术

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology

Published:2019-07 Issue:7 Volume:39 Page:3303-3309
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

EL HASSOUNI BTISSAME,MANTINI GIULIA,LI PETRI GIOVANNA,CAPULA MJRIAM,BOYD LENKA,WEINSTEIN HANNAH N.W.,VALLÉS-MARTI ANDREA,KOUWENHOVEN MATHILDE C.M.,GIOVANNETTI ELISA,WESTERMAN BART A.,PETERS GODEFRIDUS J.,

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening;Heliyon;2024-07

2. Evaluation of the combination of gemcitabine, carboplatin, and lactate dehydrogenase A inhibitor on malignant mesothelioma;Nucleosides, Nucleotides & Nucleic Acids;2024-06-20

3. Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges;Clinical Pharmacokinetics;2024-06-18

4. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells;Journal of Drug Targeting;2024-02

5. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition;Urologic Oncology: Seminars and Original Investigations;2023-12